Skljarevski V, et al. - This randomized clinical trial was performed to investigate the effect of different doses of galcanezumab vs placebo for episodic migraine prevention. For the preventive treatment of migraine, monthly subcutaneous injections of galcanezumab, both 120 mg, and 300 mg, showed efficacy (repeated-measures analysis) and supported further development in larger phase 3 studies. All dosages were found to be safe and well tolerated for the preventive treatment of episodic migraine.